$Soligenix, Inc.(SNGX)$Improving finances though launch of product delayed to 2022-2023 due to material shortages. However, product effective in trials and funded by FDA. Likely to be approved when it files for FDA approval. Good long term position for penny stock which can be expected to skyrocket once product release.